Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Diagnostics Raises $1.8M

NEW YORK (GenomeWeb News) – Precipio Diagnostics has raised $1.8 million in a Series B financing round, Connecticut Innovations, the lead investor in the round, said today.

Along with CI, which invested $750,000 in the round through its Eli Whitney Fund, Ironwood Capital, Enhanced Capital, Kuzari Capital, and individual investors participated in the financing.

Based in New Haven, Conn., Precipio provides pathology services, with a focus on cancer diagnostics. It began operations about a year-and-a-half ago and has exclusive deals with Yale School of Medicine and Yale-New Haven Hospital to analyze patients samples and report on their findings. It also licenses technologies from Yale that include a tumor profiling test suite and a prognostic biomarker for ovarian cancer.

Among the tests offered by Precipio are those based on PCR, cytogenetics, fluorescent in situ hybridization, and other technologies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.